# A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

> **NCT05007652** · PHASE2 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Multiple Myeloma and Malignant Lymphoma

## Interventions

- **DRUG:** KRN125(pegfilgrastim), PLR001(plerixafor)
- **DRUG:** KRN8601(filgrastim), PLR001(plerixafor)

## Key facts

- **NCT ID:** NCT05007652
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-10-25
- **Final completion:** 2022-10-25
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007652, "A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05007652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*